Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?

Claudio Galarza, Diana Valencia, Gabriel J. Tobón, Luis Zurita, Rubén D. Mantilla, Ricardo Pineda-Tamayo, Adriana Rojas-Villarraga, Juan C. Rueda, Juan Manuel Anaya

Resultado de la investigación: Contribución a RevistaArtículo

57 Citas (Scopus)

Resumen

The present study aimed to assess the tolerance and efficacy of rituximab (RTX), a chimeric IgG1 monoclonal antibody directed against the CD20 receptor present in B lymphocytes, in patients with autoimmune rheumatic diseases (AIRD). For this purpose, patients treated with RTX and their respective clinical charts were comprehensively examined. Indications for treatment were a refractory character of the disease, inefficacy or intolerance of other immunosuppressors. Activity indexes (SLEDAI, DAS28, and specific clinical manifestations) were used to evaluate efficacy. Serious side effects were also recorded. Seventy-four patients were included. Forty-three patients had systemic lupus erythematosus (SLE), 21 had rheumatoid arthritis (RA), 8 had Sjögren's syndrome (SS), and 2 had Takayasu's arteritis (TA). RTX was well-tolerated in 66 (89%) patients. In 8 patients (SLE=3, SS=3, RA=2), serious side effects lead to discontinuation. The mean follow-up period was 12±7.8 (2-35) months. The efficacy of RTX was registered in 58/66 (87%) patients, of whom 36 (83%) had SLE, 18/21 (85%) had RA, 3/8 (37%) had SS, and 1 had TA. The mean time of efficacy was 6.3±5.1 weeks. A significant steroid-sparing effect was noticed in half of the patients. These results add further evidence for the use of RTX in AIRD. Based on its risk-benefit ratio, RTX might be used as the first-choice treatment for patients with severe AIRD. © 2007 Humana Press Inc.
Idioma originalEnglish (US)
Páginas (desde-hasta)124-128
Número de páginas5
PublicaciónClinical Reviews in Allergy and Immunology
DOI
EstadoPublished - feb 1 2008

Huella dactilar

Rheumatic Diseases
Autoimmune Diseases
Sjogren's Syndrome
Systemic Lupus Erythematosus
Takayasu Arteritis
Rheumatoid Arthritis
Therapeutics
Rituximab
B-Lymphocytes
Immunoglobulin G
Odds Ratio
Steroids
Monoclonal Antibodies

Citar esto

Galarza, Claudio ; Valencia, Diana ; Tobón, Gabriel J. ; Zurita, Luis ; Mantilla, Rubén D. ; Pineda-Tamayo, Ricardo ; Rojas-Villarraga, Adriana ; Rueda, Juan C. ; Anaya, Juan Manuel. / Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?. En: Clinical Reviews in Allergy and Immunology. 2008 ; pp. 124-128.
@article{2499e28a25c64d4b89694e2c414681e4,
title = "Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?",
abstract = "The present study aimed to assess the tolerance and efficacy of rituximab (RTX), a chimeric IgG1 monoclonal antibody directed against the CD20 receptor present in B lymphocytes, in patients with autoimmune rheumatic diseases (AIRD). For this purpose, patients treated with RTX and their respective clinical charts were comprehensively examined. Indications for treatment were a refractory character of the disease, inefficacy or intolerance of other immunosuppressors. Activity indexes (SLEDAI, DAS28, and specific clinical manifestations) were used to evaluate efficacy. Serious side effects were also recorded. Seventy-four patients were included. Forty-three patients had systemic lupus erythematosus (SLE), 21 had rheumatoid arthritis (RA), 8 had Sj{\"o}gren's syndrome (SS), and 2 had Takayasu's arteritis (TA). RTX was well-tolerated in 66 (89{\%}) patients. In 8 patients (SLE=3, SS=3, RA=2), serious side effects lead to discontinuation. The mean follow-up period was 12±7.8 (2-35) months. The efficacy of RTX was registered in 58/66 (87{\%}) patients, of whom 36 (83{\%}) had SLE, 18/21 (85{\%}) had RA, 3/8 (37{\%}) had SS, and 1 had TA. The mean time of efficacy was 6.3±5.1 weeks. A significant steroid-sparing effect was noticed in half of the patients. These results add further evidence for the use of RTX in AIRD. Based on its risk-benefit ratio, RTX might be used as the first-choice treatment for patients with severe AIRD. {\circledC} 2007 Humana Press Inc.",
author = "Claudio Galarza and Diana Valencia and Tob{\'o}n, {Gabriel J.} and Luis Zurita and Mantilla, {Rub{\'e}n D.} and Ricardo Pineda-Tamayo and Adriana Rojas-Villarraga and Rueda, {Juan C.} and Anaya, {Juan Manuel}",
year = "2008",
month = "2",
day = "1",
doi = "10.1007/s12016-007-8028-z",
language = "English (US)",
pages = "124--128",
journal = "Clinical Reviews in Allergy and Immunology",
issn = "1080-0549",
publisher = "Humana Press",

}

Galarza, C, Valencia, D, Tobón, GJ, Zurita, L, Mantilla, RD, Pineda-Tamayo, R, Rojas-Villarraga, A, Rueda, JC & Anaya, JM 2008, 'Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?', Clinical Reviews in Allergy and Immunology, pp. 124-128. https://doi.org/10.1007/s12016-007-8028-z

Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases? / Galarza, Claudio; Valencia, Diana; Tobón, Gabriel J.; Zurita, Luis; Mantilla, Rubén D.; Pineda-Tamayo, Ricardo; Rojas-Villarraga, Adriana; Rueda, Juan C.; Anaya, Juan Manuel.

En: Clinical Reviews in Allergy and Immunology, 01.02.2008, p. 124-128.

Resultado de la investigación: Contribución a RevistaArtículo

TY - JOUR

T1 - Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?

AU - Galarza, Claudio

AU - Valencia, Diana

AU - Tobón, Gabriel J.

AU - Zurita, Luis

AU - Mantilla, Rubén D.

AU - Pineda-Tamayo, Ricardo

AU - Rojas-Villarraga, Adriana

AU - Rueda, Juan C.

AU - Anaya, Juan Manuel

PY - 2008/2/1

Y1 - 2008/2/1

N2 - The present study aimed to assess the tolerance and efficacy of rituximab (RTX), a chimeric IgG1 monoclonal antibody directed against the CD20 receptor present in B lymphocytes, in patients with autoimmune rheumatic diseases (AIRD). For this purpose, patients treated with RTX and their respective clinical charts were comprehensively examined. Indications for treatment were a refractory character of the disease, inefficacy or intolerance of other immunosuppressors. Activity indexes (SLEDAI, DAS28, and specific clinical manifestations) were used to evaluate efficacy. Serious side effects were also recorded. Seventy-four patients were included. Forty-three patients had systemic lupus erythematosus (SLE), 21 had rheumatoid arthritis (RA), 8 had Sjögren's syndrome (SS), and 2 had Takayasu's arteritis (TA). RTX was well-tolerated in 66 (89%) patients. In 8 patients (SLE=3, SS=3, RA=2), serious side effects lead to discontinuation. The mean follow-up period was 12±7.8 (2-35) months. The efficacy of RTX was registered in 58/66 (87%) patients, of whom 36 (83%) had SLE, 18/21 (85%) had RA, 3/8 (37%) had SS, and 1 had TA. The mean time of efficacy was 6.3±5.1 weeks. A significant steroid-sparing effect was noticed in half of the patients. These results add further evidence for the use of RTX in AIRD. Based on its risk-benefit ratio, RTX might be used as the first-choice treatment for patients with severe AIRD. © 2007 Humana Press Inc.

AB - The present study aimed to assess the tolerance and efficacy of rituximab (RTX), a chimeric IgG1 monoclonal antibody directed against the CD20 receptor present in B lymphocytes, in patients with autoimmune rheumatic diseases (AIRD). For this purpose, patients treated with RTX and their respective clinical charts were comprehensively examined. Indications for treatment were a refractory character of the disease, inefficacy or intolerance of other immunosuppressors. Activity indexes (SLEDAI, DAS28, and specific clinical manifestations) were used to evaluate efficacy. Serious side effects were also recorded. Seventy-four patients were included. Forty-three patients had systemic lupus erythematosus (SLE), 21 had rheumatoid arthritis (RA), 8 had Sjögren's syndrome (SS), and 2 had Takayasu's arteritis (TA). RTX was well-tolerated in 66 (89%) patients. In 8 patients (SLE=3, SS=3, RA=2), serious side effects lead to discontinuation. The mean follow-up period was 12±7.8 (2-35) months. The efficacy of RTX was registered in 58/66 (87%) patients, of whom 36 (83%) had SLE, 18/21 (85%) had RA, 3/8 (37%) had SS, and 1 had TA. The mean time of efficacy was 6.3±5.1 weeks. A significant steroid-sparing effect was noticed in half of the patients. These results add further evidence for the use of RTX in AIRD. Based on its risk-benefit ratio, RTX might be used as the first-choice treatment for patients with severe AIRD. © 2007 Humana Press Inc.

U2 - 10.1007/s12016-007-8028-z

DO - 10.1007/s12016-007-8028-z

M3 - Article

SP - 124

EP - 128

JO - Clinical Reviews in Allergy and Immunology

JF - Clinical Reviews in Allergy and Immunology

SN - 1080-0549

ER -